Functional Status, Quality of Life and Survival After Repeated Intrathecal Administration of Autologous Lineage-Negative Cells in Amyotrophic Lateral Sclerosis
Authors:
- Monika Gołąb-JanowskaMGMonika Gołąb-Janowska
- Agnieszka Wełnicka-WesołowskaAWAgnieszka Wełnicka-Wesołowska
- Bartłomiej BaumertBBBartłomiej Baumert
- Karolina Machowska-SempruchKMKarolina Machowska-Sempruch
- Agnieszka MellerAMAgnieszka Meller
- Anna SobuśASAnna Sobuś
- Edyta PaczkowskaEPEdyta Paczkowska
- Dariusz KotlęGaDKDariusz KotlęGa
- Przemysław NowackiPNPrzemysław Nowacki
- Bogusław MachalińskiBMBogusław Machaliński
Open Access
- 14 October 2026
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7937
Abstract
Background/Objectives: Adjuvant cell-based strategies are still being explored in amyotrophic lateral sclerosis (ALS). Materials and Methods: In this open-label, single-arm study of intrathecal autologous bone marrow-derived lineage-negative (LIN−) cells, we report functional status, quality of life, and survival after three administrations at six-week intervals. A total of 45 patients with sporadic ALS were qualified: 42 received all three administrations and 23 completed the 24-week assessment schedule, while 19 stopped attending because of deterioration. Results: In the 23 completers, Norris scale scores were stable until week 13 and then declined (p = 0.00004), and the Amyotrophic Lateral Sclerosis Assessment Questionnaire 40 (ALSAQ-40) followed the same pattern (p = 0.0019), whereas the ALS Functional Rating Scale—Revised (ALSFRS-R) declined at a constant 0.5 points per month. In all 42 treated patients the Norris score fell during treatment (0.95 points per month; 95% CI 0.52–1.38), so the plateau was confined to completers, who had milder baseline disease. Dose-related differences in quality of life were confounded by baseline imbalance; survival analyses were exploratory. Cell number did not correlate with cerebrospinal fluid brain-derived neurotrophic factor (BDNF) after the third administration in the 39 patients with paired samples (ρ = 0.14). No adverse event was recorded in 126 procedures, but harms were not graded systematically. Conclusions: These exploratory findings do not demonstrate efficacy; a sham-controlled trial with blinded raters is required.Keywords
Funding Information
- Narodowe Centrum Badań i Rozwoju (STRATEGMED1/234261/2/NCBR/2014)
This publication has 50 references indexed in Scilit:
- A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosisMuscle & Nerve, 2022
- Validation of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale in Poland and its reliability in conditions of the medical experimentNeurological Sciences, 2020
- Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysisJournal of Neurology, 2019
- Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral SclerosisAnnals of Neurology, 2018
- Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral SclerosisJAMA Neurology, 2016
- Glial cells in amyotrophic lateral sclerosisExperimental Neurology, 2014
- Neurotrophic Bone Marrow Cellular Nests Prevent Spinal Motoneuron Degeneration in Amyotrophic Lateral Sclerosis Patients: A Pilot Safety StudyStem Cells, 2012
- Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)Cochrane Database of Systematic Reviews, 2012
- Mechanisms Underlying Inflammation in NeurodegenerationCell, 2010
- The ALS Health Profile Study: quality of life of amyotrophic lateral sclerosis patients and carers in EuropeJournal of Neurology, 2000